Autorefractometry is less accurate in LASIK eyes

Article

It has been demonstrated that autorefractometry is less accurate in eyes that have undergone LASIK when compared with non-operated eyes, according to a recent study published in the American Journal of Ophthalmology.

It has been demonstrated that autorefractometry is less accurate in eyes that have undergone LASIK when compared with non-operated eyes, according to a recent study published in the American Journal of Ophthalmology.

Led by Thomas Kohnen et al., Department of Ophthalmology, Medical Centre of J.W. Goethe-University, Frankfurt, Germany, the researchers examined the factors influencing the reliability of autorefractometry before and after LASIK for myopia and myopic astigmatism.

The study group comprised a total of 250 consecutive eyes belonging to 132 patients with an average preoperative spherical equivalent of the subjective refraction (SR) of -6.59 D. All patient data was reviewed before LASIK and 1 month afterwards, including SR, objective automated reaction (AR) and visual acuity.

Additionally, subgroup analysis was performed with regards to preoperative myopia and excimer laser optical zone (OZ).

The mean post-LASIK spherical equivalent difference was +0.13±0.51 D in comparison with a preoperative difference in spherical equivalent of –0.30±0.58 D. The respective postoperative difference between spherical equivalents by optical zone size were as follows: for small OZ (5.0–5.5 mm) = –0.61 D; for OZ 5.6–6.0 mm = –0.36 D; and for 6.1–7.0 mm = –0.16 D. Further, the higher the preoperative myopia, the increasingly myopic the AR when compared with the SR.

Based on the results, the authors concluded that the reliability of automated refraction is lowered following LASIK and this is influenced by the excimer laser optical zone size and the preoperative myopia. Specifically, refraction was less accurate with a small OZ and high preoperative myopia.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.